Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

• Main Authors: Craig Leonardi (Author), Kristian Reich (Author), Peter Foley (Author), Hideshi Torii (Author), Sascha Gerdes (Author), Lyn Guenther (Author), Melinda Gooderham (Author), Laura K. Ferris (Author), Christopher E. M. Griffiths (Author), Hany ElMaraghy (Author), Heidi Crane (Author), Himanshu Patel (Author), Russel Burge (Author), Gaia Gallo (Author), David Shrom (Author), Ann Leung (Author), Chen-Yen Lin (Author), Kim Papp (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2020-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for treatment of moderate-to-severe plaque psoriasis. Our objective was to evaluate the long-term efficacy and safety of ixekizumab in moderate-to-severe plaque psoriasis throu...